PHVS

Market-moving news on Pharvaris (NASDAQ: PHVS): filings, earnings, deals and other events, from REDFILED.

Pharvaris is developing an oral tablet for the prevention of hereditary angioedema attacks.

PHVS

PHARVARIS Phase 3 Prophylaxis Trial Cuts HAE Attacks by 83%

Deucrictibant XR met the primary endpoint and all secondary endpoints in CHAPTER-3, clearing the way for filings starting in the first half of 2027.